ARDX Strong upgrade from a top financial firm

13 เม.ย. 2022

ARDX Ardelyx is a biopharmaceutical company that discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the US and internationally.

On 3/2/2022 Jefferies Financial Group Upgraded ARDX from Hold to Buy raising the price target from $1.00 to $5.00
This would be a 581% gain from the current level.

Looking forward to read your opinion about it.

31 มี.ค. 2023

ปิดการเทรด: ถึงเป้าหมายการทำกำไร

Target reached! 6X gain!